1-6 of 6
Joseph I. Clark
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma

David F. McDermott, Su-Chun Cheng, Sabina Signoretti, Kim A. Margolin, Joseph I. Clark, Jeffrey A. Sosman, Janice P. Dutcher, Theodore F. Logan, Brendan D. Curti, Marc S. Ernstoff, Leonard Appleman, Michael K.K. Wong, Nikhil I. Khushalani, Leslie Oleksowicz, Ulka N. Vaishampayan, James W. Mier, David J. Panka, Rupal S. Bhatt, Alexandra S. Bailey, Bradley C. Leibovich, Eugene D. Kwon, Fairooz F. Kabbinavar, Arie S. Belldegrun, Robert A. Figlin, Allan J. Pantuck, Meredith M. Regan, Michael B. Atkins
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (3): 561–568.
https://doi.org/10.1158/1078-0432.CCR-14-1520
Published: 01 February 2015
View article titled, The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma
Open the PDF for The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma in another window
Journal Articles

Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer

Kim Margolin, Michael B. Atkins, Janice P. Dutcher, Marc S. Ernstoff, John W. Smith, II, Joseph I. Clark, Joseph Baar, Jeffrey Sosman, Jeffrey Weber, Chetan Lathia, Janice Brunetti, Frank Cihon, Brian Schwartz
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (11): 3312–3319.
https://doi.org/10.1158/1078-0432.CCR-06-1341
Published: 01 June 2007
View article titled, Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer
Open the PDF for Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer in another window
Journal Articles

Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer (SWOG 9806): Carboplatin/Gemcitabine followed by Paclitaxel or Cisplatin/Vinorelbine followed by Docetaxel

Martin J. Edelman, Joseph I. Clark, Kari Chansky, Kathy Albain, Nirmala Bhoopalam, Geoffrey R. Weiss, Jeffrey K. Giguere, Karen Kelly, John Crowley, David R. Gandara
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (15): 5022–5026.
https://doi.org/10.1158/1078-0432.CCR-04-0002
Published: 05 August 2004
View article titled, Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer (SWOG 9806): <subtitle>Carboplatin/Gemcitabine followed by Paclitaxel or Cisplatin/Vinorelbine followed by Docetaxel</subtitle>
Open the PDF for Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer (SWOG 9806): <subtitle>Carboplatin/Gemcitabine followed by Paclitaxel or Cisplatin/Vinorelbine followed by Docetaxel</subtitle> in another window
Journal Articles

Dendritic Cells Transduced with Full-Length Wild-Type p53 Generate Antitumor Cytotoxic T Lymphocytes from Peripheral Blood of Cancer Patients

Ekaterina Yu. Nikitina, Joseph I. Clark, James van Beynen, Sunil Chada, Arvind K. Virmani, David P. Carbone, Dmitry I. Gabrilovich
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (1): 127–135.
Published: 01 January 2001
View article titled, Dendritic Cells Transduced with Full-Length Wild-Type p53 Generate Antitumor Cytotoxic T Lymphocytes from Peripheral Blood of Cancer Patients
Open the PDF for Dendritic Cells Transduced with Full-Length Wild-Type p53 Generate Antitumor Cytotoxic T Lymphocytes from Peripheral Blood of Cancer Patients in another window
Journal Articles

Clinical Significance of Defective Dendritic Cell Differentiation in Cancer

Bond Almand, John R. Resser, Brian Lindman, Sorena Nadaf, Joseph I. Clark, Eugene D. Kwon, David P. Carbone, Dmitry I. Gabrilovich
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (5): 1755–1766.
Published: 01 May 2000
View article titled, Clinical Significance of Defective Dendritic Cell Differentiation in Cancer
Open the PDF for Clinical Significance of Defective Dendritic Cell Differentiation in Cancer in another window
Journal Articles

Daily Subcutaneous Ultra-Low-Dose Interleukin 2 with Daily Low-Dose Interferon-α in Patients with Advanced Renal Cell Carcinoma

Joseph I. Clark, Ellen R. Gaynor, Brenda Martone, Susan C. Budds, Rajini Manjunath, Robert C. Flanigan, W. Bedford Waters, Jeffrey A. Sosman
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (9): 2374–2380.
Published: 01 September 1999
View article titled, Daily Subcutaneous Ultra-Low-Dose Interleukin 2 with Daily Low-Dose Interferon-α in Patients with Advanced Renal Cell Carcinoma
Open the PDF for Daily Subcutaneous Ultra-Low-Dose Interleukin 2 with Daily Low-Dose Interferon-α in Patients with Advanced Renal Cell Carcinoma in another window